This week’s research highlights how both everyday habits and emerging therapeutics may influence healthspan and longevity. New findings explore the relationship between specific stages of sleep and long-term disease risk, the cardiometabolic benefits of whole grains, the long-awaited effort to test metformin as a treatment targeting aging itself, and intriguing early evidence from an AI-discovered drug that may affect markers of biological aging.
Are you part of a health or life extension research organization? Our coalition has grown to over 90 member groups, including 25 major US organizations and 16 major international groups. We hope your organization will be next! Check below to find a link to join our coalition quickly and easily.
All this and more this week. Join us as we move forward into another exciting month of incredible opportunities in this burgeoning and revolutionary field.
Edwina Rogers, CEO
Global Healthspan Policy Institute
Facebook
Twitter
LinkedIn
More dream sleep linked to lower risk of 83 diseases, including diabetes
An analysis of nearly 100,000 UK Biobank participants found that greater REM sleep was associated with a lower risk of 83 diseases over nearly nine years of follow-up, while greater deep sleep was associated with reduced risk of several conditions including type 2 diabetes and Parkinson’s disease.
Daily whole grains could support heart health, weight loss
A meta-analysis of randomized controlled trials involving more than 6,500 participants found that consuming roughly 60–100 grams, or four to six servings, of whole grains per day was associated with reductions in body weight, waist circumference, total cholesterol and the inflammatory marker IL-6.
The TAME trial: Can a common diabetes drug extend human life span?
The proposed Targeting Aging with Metformin trial aims to test whether the widely used diabetes drug can delay multiple age-related diseases in 3,000 adults ages 65–79, potentially providing one of the first large randomized tests of a drug designed to target aging rather than a single disease.
AI drug rentosertib may slow aging. What testing found.
An exploratory analysis of a small Phase 2a trial of the AI-discovered drug rentosertib found reductions in several proteomic measures of predicted biological age, raising the possibility that drugs developed for age-related diseases such as pulmonary fibrosis could also influence broader aging biology, though the early findings do not establish that the drug slows human aging or extends lifespan.
